Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis - Real-World Effectiveness in UK Clinical Practice (CAMELOT-MS)
Latest Information Update: 29 Dec 2023
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CAMELOT-MS
- Sponsors Merck KGaA
- 20 Dec 2023 Status changed from active, no longer recruiting to completed.
- 01 Sep 2023 Planned End Date changed from 15 Oct 2023 to 27 Oct 2023.
- 01 Sep 2023 Planned primary completion date changed from 15 Oct 2023 to 27 Oct 2023.